Trial Profile
Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination With Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vaginal Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 08 Dec 2023
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; OCX 191 (Primary) ; OCX 191 (Primary)
- Indications Adenocarcinoma; Adenosquamous carcinoma; Cervical cancer; Squamous cell cancer; Vaginal intraepithelial neoplasia; Vulvar intraepithelial neoplasia
- Focus Adverse reactions; Pharmacokinetics
- 28 Nov 2023 Planned End Date changed from 31 Dec 2023 to 26 Nov 2024.
- 30 Jun 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 30 Jun 2023 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2023.